普洛药业：全资子公司获阿莫西林克拉维酸钾片药品注册证书

Core Viewpoint - Prolo Pharmaceutical's subsidiary, Zhejiang Prolo Jutai Pharmaceutical Co., Ltd., has received a drug registration certificate for Amoxicillin Clavulanate Potassium Tablets from the National Medical Products Administration, which is expected to enhance market competitiveness and sales potential in the Chinese hospital market [1] Group 1: Product and Market Information - The drug is indicated for the treatment of upper respiratory infections, lower respiratory infections, urinary system infections, skin and soft tissue infections, and oral infections [1] - The projected market size for the Chinese hospital market in 2024 is 760 million tablets, with a sales value of 620 million yuan [1] Group 2: R&D and Regulatory Aspects - Cumulative R&D investment for the drug has reached 10.8245 million yuan [1] - The drug is considered to have passed the consistency evaluation of generic drug quality and efficacy, qualifying it for participation in the national drug centralized procurement renewal [1]